CASI Pharmaceuticals announced that Mr. Wei (Larry) Zhang will no longer serve as Senior Vice President. The departure is part of ongoing efforts to streamline branches, personnel, and related activities in the United States. CASI Pharmaceuticals operates as a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
